Search

Introduction Fulvestrant demonstrated benefits in overall survival and progression-free survival in patients with advanced breast cancer, who are hormone receptor-positive and human epidermal growth factor receptor 2 negative. The characteristics, evolution, and survival of patients with hormone receptor-positive, HER2-negative breast cancer treated with fulvestrant were evaluated according to the national treatment coverage protocols of the National Resources Fund, with the aim of understanding the efficacy of fulvestrant in patients treated in usual clinical practice and comparing our results with those from pivotal studies. Methods A database from the National Resources Fund covering the period from 2009 to 2022 was used. Survival curves were assessed using the Kaplan-Meier method, and differences were analyzed using the Log-Rank test. Results A total of 1085 patients with an average age of 63,66 years were included. Following a follow-up of 14 months, the median overall survival was 16 months, and the median progression-free survival was 6 months. The presence of liver and bone metastases was associated with a shorter overall survival. Patients from the public sector and those with a better performance status experienced longer overall survival. Conclusions Our findings provide a valuable perspective for treatment management in a context of limited resources. Overall survival and progression-free survival were somewhat lower than those reported in pivotal clinical trials. The presence of liver and bone metastases was associated with worse prognosis and survival; additionally, patients with worse performance status had shorter overall survival. These findings underscore the need for personalized therapies, opening new lines of future research.

Introduction: Fulvestrant demonstrated benefits in overall survival and progression-free survival in patients with advanced breast cancer, who are hormone receptor-positive and human epidermal growth factor receptor 2 negative. The characteristics, evolution, and survival of patients with hormone receptor-positive, HER2-negative breast cancer treated with fulvestrant were evaluated according to the national treatment coverage protocols of the National Resources Fund, with the aim of understanding the efficacy of fulvestrant in patients treated in usual clinical practice and comparing our results with those from pivotal studies., Methods: A database from the National Resources Fund covering the period from 2009 to 2022 was used. Survival curves were assessed using the Kaplan-Meier method, and differences were analyzed using the Log-Rank test., Results: A total of 1085 patients with an average age of 63,66 years were included. Following a follow-up of 14 months, the median overall survival was 16 months, and the median progression-free survival was 6 months. The presence of liver and bone metastases was associated with a shorter overall survival. Patients from the public sector and those with a better performance status experienced longer overall survival., Conclusions: Our findings provide a valuable perspective for treatment management in a context of limited resources. Overall survival and progression-free survival were somewhat lower than those reported in pivotal clinical trials. The presence of liver and bone metastases was associated with worse prognosis and survival; additionally, patients with worse performance status had shorter overall survival. These findings underscore the need for personalized therapies, opening new lines of future research., Competing Interests: The authors have no conflict of interest., (This work is licensed under a Creative Commons Attribution 4.0 International License.)

Background: Diffusion-weighted imaging (DWI) plays an important role in the differentiation of malignant and benign breast lesions.Purpose: To investigate the utility of various diffusion parameters obtained from monoexponential, biexponential, and stretched-exponential DWI models in the differential diagnosis of breast lesions.Study Type: Prospective.Population: Sixty-one patients (age range: 25-68 years old; mean age: 46 years old) with 31 malignant lesions, 42 benign lesions, and 28 normal breast tissues diagnosed initially by clinical palpation, ultrasonography, or conventional mammography were enrolled in the study from January to September 2016.Field Strength: 3.0T MR scanner, T1 WI, T2 WI, DWI (conventional and multi-b values), dynamic contrast-enhanced.Assessment: The apparent diffusion coefficient (ADC) was calculated by monoexponential analysis. The diffusion coefficient (ADCslow ), pseudodiffusion coefficient (ADCfast ), and perfusion fraction (f) were calculated using the biexponential model. The distributed diffusion coefficient (DDC) and water molecular diffusion heterogeneity index (α) were obtained using a stretched-exponential model. All parameters were compared for malignant tumors, benign tumors, and normal breast tissues. A receiver operating characteristic curve was used to compare the ability of these parameters, in order to differentiate benign and malignant breast lesions.Statistical Tests: All statistical analyses were performed using statistical software (SPSS).Results: ADC, ADCslow , f, DDC, and α values were significantly lower in malignant tumors when compared with normal breast tissues and benign tumors (P < 0.05). However, ADC and f had higher area under the receiver operating characteristic curve (AUC) values (0.889 and 0.919, respectively).Data Conclusion: The parameters derived from the biexponential and stretched-exponential DWI could provide additional information for differentiating between benign and malignant breast tumors when compared with conventional diffusion parameters.Level Of Evidence: 4 Technical Efficacy: Stage 4 J. Magn. Reson. Imaging 2019;50:1461-1467. [ABSTRACT FROM AUTHOR]

Introducción. Los cánceres triple negativo (CTN) son aquellos que no presentan receptores de estrógeno, progesterona ni human epidermal grow factor, receptor type 2. Herceptin (HER2). Tienden a ser más agresivos; a menudo se diagnostican en pacientes jóvenes, a veces como cánceres de intervalo, llegan a ser de gran tamaño y más frecuentemente presentan metástasis axilares al momento del diagnóstico. Su pronóstico es peor que otros cánceres mamarios, existiendo una mayor probabilidad de recurrencia a distancia y de muerte, especialmente en los primeros 5 años. Pacientes y métodos. Se efectuó una revisión retrospectiva descriptiva de los casos de CTN diagnosticados en nuestra institución (periodo entre marzo de 2005 y junio de 2012) con el fin de identificar sus características imaginológicas. Resultados. Los CTN pueden quedar ocultos en mamografía (Mx) si el parénquima es denso (tipo ACR 3 y 4), puesto que aparecen principalmente como masas o asimetrías focales, sin microcalcificaciones. Tanto en Mx como en ultrasonido (US) pueden evocar una lesión de morfología benigna. En US se manifiestan frecuentemente como un nódulo sólido único, marcadamente hipoecogénico con refuerzo posterior, de contornos bastante circunscritos y que aparece hipo/avascular al Doppler color (o vascularizado en la periferia sin vasos centrales) y varios pedículos aferentes. La resonancia magnética (RM) identifica hallazgos claramente sospechosos con algunos elementos característicos: masa cuya localización es preferentemente posterior, pre-pectoral, marcadamente hiperintensa en T2 que capta el contraste en anillo y presenta curva de lavado, a veces con septos hipercaptantes en el centro de la lesión. Conclusión. Los CTN presentan a menudo características en imágenes que los diferencian de otros tipos de tumores.Introduction. Triple-negative cancers (TNC) refers to any breast cancer that does not express the genes for estrogen receptor (ER), progesterone receptor (PR) or human epidermal grow factor, receptor type 2. Herceptin (HER2). They tend to be more aggressive; often being diagnosed in young patients, sometimes as interval cancers, they can grow to be large in size and patients frequently present initially with axillary metastases. They show a worse prognosis compared to other breast cancer tumors, with an increased risk of distant recurrence and death, especially in the first 5 years after diagnosis. Patients and methods. We conducted a descriptive, retrospective observational study of TNC cases diagnosed at our institution between March 2005 and June 2012 in order to identify their imaging features. Results. TNC may not be seen on mammography (Mx) if the parenchyma is dense (ACR types 3 and 4), mainly because they appear as masses or focal asymmetries without microcalcifications. Both on mammography and ultrasound (US) they can evoke a benign lesion. On US studies they frequently manifest as a solid single nodule, markedly hypoechoic with posterior acoustic enhancement and well-defined contours. They appear hypo/ avascular on color Doppler examinations (or vascularized in the periphery without central vessels) and various afferent pedicles may be present. Magnetic resonance imaging (MRI) clearly identifies suspicious lesions with some characteristic features: mass preferably with posterior and prepectoral location, markedly hyperintense on T2- weighted images with a ring-like pattern of contrast agent uptake, presenting washout curve, sometimes with septa increased uptake in the lesion center. Conclusion. Triple receptor-negative cancers often exhibit imaging features that distinguish them from other types of tumors.

Se realizó un estudio retrospectivo y comparativo tomando como universo 530 pacientes portadoras de cáncer de mama en las etapas I y II de la enfermedad, operadas en el servicio de Cirugía General del Hospital Clínico Quirúrgico "Abel Santamaría Cuadrado" de Pinar del Río, en el período de tiempo comprendido entre el 1ero. de Enero de 1988 y el 31 de Diciembre de 2003, las que fueron intervenidas por diferentes técnicas, 345 (65,09%) con proceder conservador y 185 (34,90%) con técnicas radicales (Patey, mastectomía total ampliada y mastectomía simple). El comportamiento de las recidivas locales fue significativo (pAimed at assessing breast cancer behaviour according to operative procedures a retrospective and comparative study was conducted taking as universe 530 female patients suffering from breast cancer (I and II stages of the disease) at Abel Santamaría University Hospital during the period of January 1st, 1998 and December 31, 2003 using different operative procedures, 345 (65.09 %) with conservative operative procedure and 185 (34.90 %) with radical mastectomy (Patey total wide mastectomy and simple mastectomy). Behaviour of local relapses was significant (p < 0.005) in favour of conservative operation 9.59 % and 18.37 % of radical operative procedures; a similar behaviour was present with distant metastases 8.11 % in those treated conservatively and 20.0 % in radical treatments. Global survival in 5 years favoured those patients who underwent conservative operation (90.47 %) in relation to those with radical mastectomy (73.64 %) p < 0.005.

Acute non-lymphocytic leukaemia (ANLL) occurs with increased frequency in women with previously diagnosed breast cancer. Adjuvant radiotherapy and chemotherapy are related to this increase. We studied the interrelationships among age at breast cancer diagnosis, interval to ANLL diagnosis, and survival in 54 women of whom 11 were from Kansas and 43 were from two other published series. Median age at breast cancer diagnosis was 50.5 years, median interval to ANIL diagnosis was 4.8 years, and median survival after ANLL diagnosis was 2.2 months. Increasing age was associated with a decrease of the interval to ANLL diagnosis just short of statistical significance (P=0.0591). There was no association of survival with either age or the interval to ANLL diagnosis. With an increase in the use of adjuvant therapy in breast cancer there is a need to identifier women at greatest risk of subsequently developing ANLL, at present not possible. [ABSTRACT FROM AUTHOR]

Abstract: Objectives: To obtain perfusion as well as diffusion information in normal breast tissues and breast lesions from intravoxel incoherent motion (IVIM) imaging with biexponential analysis of multiple b-value diffusion-weighted imaging (DWI) and compare these parameters to apparent diffusion coefficient (ADC) obtained with monoexponential analysis in their ability to discriminate benign lesions and malignant tumors. Materials and methods: In this prospective study, informed consent was acquired from all patients. Eighty-four patients with 40 malignant tumors, 41 benign lesions, 30 simple cysts and 39 normal breast tissues were imaged at 1.5T utilizing contrast-enhanced magnetic resonance imaging (MRI) and DWI using 12 b values (range: 0–1000s/mm2). Tissue diffusivity (D), perfusion fraction (f) and pseudo-diffusion coefficient (D*) were calculated using segmented biexponential analysis. ADC (b =0 and 1000s/mm2) was calculated with monoexponential fitting of the DWI data. D, f, D* and ADC values were obtained for normal breast tissues, simple cysts, benign lesions and malignant tumors. Receiver operating characteristic analysis was performed for all DWI parameters. Results: There was good interobserver agreement on the measurements between the 2 observers. D values were significantly different among malignant tumors, benign lesions, simple cysts and normal breast tissues (P =0.000) and it was the same result for f, D* and ADC values. Further comparisons of these 4 parameters between every single pair were as the following. D and ADC values of malignant tumors were significantly smaller than those of benign lesions, simple cysts and normal tissues (P =0.000, respectively). The f value of malignant tumors was significantly higher than that of benign lesions, simple cysts and normal breast tissues (P =0.001, P =0.000, and P =0.000). D and ADC values demonstrated higher sensitivity and specificity in differentiating benign lesions and malignant tumors, with area under the curve (AUC) of 0.952 and 0.945, respectively, while f and D* with the lower AUC of 0.723 and 0.630, respectively. Combining f and D values had a sensitivity up to 98.75%. Conclusion: DWI response curves in malignant tumors, benign lesions and normal fibroglandular tissues are found to be biexponential fit in comparison with the monoexponential fit for simple cysts. IVIM provides separate quantitative measurement of D for cellularity and f and D* for vascularity and is helpful for differentiation between benign and malignant breast lesions. [Copyright &y& Elsevier]